The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Fatty acids, inflammation, and asthma

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Exposure of infants to budesonide through breast milk of asthmatic mothers Anette Fält, BSc, Thomas Bengtsson, MSc, Britt-Marie Kennedy, BSc, Ann Gyllenberg,

Is 9 more than 2 also in allergic airway inflammation?

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial Marko Kalliomäki, MD, PhD,

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Fatty acids, inflammation, and asthma

Badrul A. Chowdhury, MD, PhD

The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction MyLinh Duong, MBBS, Reshma Amin, MD, Adrian J.

NAEPP Expert Panel Report

Rising prevalence of asthma is sex-specific in a US farming population

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Katherine A. Vierk, MPH, Kathleen M. Koehler, PhD, MPH, Sara B

Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients William W. Busse, MD, Sally E. Wenzel, MD, Eli O. Meltzer,

Safety of formoterol in patients with asthma: Combined analysis of data from double- blind, randomized controlled trials Harold Nelson, MD, Catherine.

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Tari Haahtela, MD, PhD, Klaus Tamminen, MD, Tuomo Kava, MD, PhD, L

Nonadherence to Asthma Treatment: Getting Unstuck

Reply Journal of Allergy and Clinical Immunology

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Acute asthma intervention: Insights from the STAY study

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

What is an “eosinophilic phenotype” of asthma?

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Clinical need for a nebulized corticosteroid

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Personalized asthma therapy in blacks—the role of genetic ancestry

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Bruce G. Bender, PhD, Alex Pedan, PhD, Laleh T. Varasteh, RPh, MSF

Therapeutic strategies to reduce asthma exacerbations

One step forward, 2 steps back: The enigma of preschool wheeze

Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy Padmaja Subbarao, MD, MSc, Sandra C. Dorman,

The Editors' Choice Journal of Allergy and Clinical Immunology

Exposure of infants to budesonide through breast milk of asthmatic mothers Anette Fält, BSc, Thomas Bengtsson, MSc, Britt-Marie Kennedy, BSc, Ann Gyllenberg,

Risk of oral food challenges

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen- induced asthmatic reactions Emmerentia van Schalkwyk, MBChB, K. Strydom,

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

Macrolide antibiotics and asthma treatment

Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma Stanley J. Szefler, MD, Lars-Goran Carlsson,

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Environmental factors and eosinophilic esophagitis

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Modeling asthma exacerbations through lung function in children

Presentation transcript:

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in mild persistent asthma William W. Busse, MD, Søren Pedersen, MD, Romain A. Pauwels, MD, Wan C. Tan, MD, Yu-Zhi Chen, MD, Carl Johan Lamm, PhD, Paul M. O'Byrne, MD Journal of Allergy and Clinical Immunology Volume 121, Issue 5, Pages 1167-1174 (May 2008) DOI: 10.1016/j.jaci.2008.02.029 Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Study design. Patients were randomized to double-blind treatment with inhaled budesonide, 200 μg (aged <11 years) or 400 μg once daily through a Turbuhaler, or placebo plus usual asthma therapy for 3 years. After 3 years, all patients received 2 years of open-label treatment with inhaled budesonide once daily plus usual asthma therapy. Journal of Allergy and Clinical Immunology 2008 121, 1167-1174DOI: (10.1016/j.jaci.2008.02.029) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Patient disposition during the 2-year open-label phase of the study. The number of patients who received double-blind treatment was 7221. Journal of Allergy and Clinical Immunology 2008 121, 1167-1174DOI: (10.1016/j.jaci.2008.02.029) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Mean postbronchodilator (A) and prebronchodilator (B) percent predicted FEV1 among patients in the budesonide and reference groups completing all 5 years of the study. Journal of Allergy and Clinical Immunology 2008 121, 1167-1174DOI: (10.1016/j.jaci.2008.02.029) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Cumulative probability of having a first SARE. The curves are based on life-table estimates (interval width, 0.25 years) by using all patients entered into the study. The number of patients at risk in the budesonide (Reference) group is 3597 (3568) at time 0, 2613 (2486) at time 2.50 years, and 2337 (2195) at time 4.50 years. Journal of Allergy and Clinical Immunology 2008 121, 1167-1174DOI: (10.1016/j.jaci.2008.02.029) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Mean percentage of symptom-free days (SFDs) among patients in the budesonide and reference groups completing all 5 years of the study. Journal of Allergy and Clinical Immunology 2008 121, 1167-1174DOI: (10.1016/j.jaci.2008.02.029) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions